Results 61 to 70 of about 3,353 (184)
In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies) [PDF]
, 2022 [Objectives] To study the in vitro activity of imipenem/relebactam and comparators and the imipenem/relebactam resistance mechanisms in a Pseudomonas aeruginosa collection from Portugal (STEP, 2017-18) and Spain (SUPERIOR, 2016-17) surveillance studies ...
Vieira, Ana Raquel +28 more
core +1 more source
Journal of Antimicrobial Chemotherapy, 2021 Abstract Background Imipenem/relebactam is a novel carbapenem/β-lactamase inhibitor combination, developed to act against carbapenemase-producing Enterobacterales (CPE). Objectives To assess the in vitro activity of imipenem ...
Juan Carlos Vázquez-Ucha +40 more
openaire +5 more sources
Acta Crystallographica Section D, Volume 82, Issue 6, Page 587-602, June 2026.This review describes how an integrated structural biology platform at Merck Sharp & Dohme LLC, Rahway, New Jersey, USA, combining X‐ray crystallography, cryo‐EM, MicroED and cryo‐ET, enables seamless three‐dimensional insights from molecular to cellular length scales.
Jill E. Chrencik +44 more
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 6, June 2026.ABSTRACT Nacubactam is a β‐lactamase inhibitor. Early‐phase studies with 1000/2000/4000/8000 mg nacubactam monotherapy were not powered to assess proarrhythmic risk. Therefore, this analysis pooled electrocardiogram data from two placebo‐controlled studies to quantify potential effects of nacubactam on cardiac repolarization.
Jun Morita, Sue McKendrick, Yuji Kumagai
wiley +1 more source
ChemMedChem, Volume 21, Issue 9, 14 May 2026.Combining enhanced permeability strategies with (2‐pyridyl)methylene substitution in the sulbactam scaffold led to a novel β‐lactamase inhibitor to combat β‐lactamase‐mediated resistance to β‐lactam antibiotics. The studies presented highlight the potential of compound 3 as a next‐generation β‐lactamase inhibitor for combating infections caused by ...
Diana Rodríguez +4 more
wiley +1 more source
Journal of Clinical Laboratory Analysis, Volume 40, Issue 10, May 2026.The primary mechanism of carbapenem resistance identified in pediatric CRKP‐BSI strains was the production of Class B metalloenzymes. We report, for the first time, an outbreak of bloodstream infections in a neonatal ward caused by the dissemination of NDM‐1‐producing ST25 K. pneumoniae.
Mingming Zhou +8 more
wiley +1 more source
An efficient and practical approach to synthesis of relebactam
Synthetic CommunicationsA novel and practical seven-step synthesis of relebactam has been developed, starting from (2 R,5S)-5-((benzyloxy)amino)piperidine-2-carboxylic acid, achieving an overall yield of 42.27% with high HPLC purity (99.27%). This approach offers an efficient synthesis of the key diazabicyclooctane (DBO) core, while also demonstrating cost-effectiveness and ...
Qiu, Baojie +4 more
openaire +1 more source
, 2017 We determined imipenem, imipenem-relebactam, ceftazidime, and ceftazidime-avibactam MICs against 100 CRE isolates that underwent whole-genome sequencing.
Palash Samanta +6 more
core +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 608-617, March 2026.This manuscript describes the scope of implementation and impact of a regulatory agency‐qualified panel of six urine biomarkers on drug development, the process for which was conducted and funded by the Critical Path Institute, the Foundation for the National Institutes of Health, and the United States Food and Drug Administration.
Tanja S. Zabka +7 more
wiley +1 more source
Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics
MicrobiologyOpen, Volume 15, Issue 1, February 2026.Molecular reversal strategies against antibiotic resistance act through three mechanisms: inhibiting resistance gene function, blocking horizontal gene transfer, and modulating host defense. Emerging technologies, such as CRISPR‐Cas gene editing, photodynamic therapy, nanotechnology, and ecological competition, further strengthen these approaches ...
Tianjiao Li +4 more
wiley +1 more source